Summary
Total platinum contents and cisplatin–DNA adduct levels were determined in vivo in xenografted tumour tissues in mice and in vitro in cultured tumour cells of head and neck squamous cell carcinoma (HNSCC), and correlated with sensitivity to cisplatin. In vivo, a panel of five HNSCC tumour lines growing as xenografts in nude mice was used. In vitro, the panel consisted of five HNSCC cell lines, of which four had an in vivo equivalent. Sensitivity to cisplatin varied three- to sevenfold among cell lines and tumours respectively. However, the ranking of the sensitivities of the tumour lines (in vivo), also after reinjection of the cultured tumour cells, did not coincide with that of the corresponding cell lines, which showed that cell culture systems are not representative for the in vivo situation. Both in vitro and in vivo, however, significant correlations were found between total platinum levels, measured by atomic absorption spectrophotometry (AAS), and tumour response to cisplatin therapy at all time points tested. The levels of the two major cisplatin–DNA adduct types were determined by a recently developed and improved 32P post-labelling assay at various time points after cisplatin treatment. Evidence is presented that the platinum–AG adduct, in which platinum is bound to guanine and an adjacent adenine, may be the cytotoxic lesion because a significant correlation was found between the platinum–AG levels and the sensitivities in our panel of HNSCC, in vitro as well as in vivo. This correlation with the platinum–AG levels was established at 1 h (in vitro) and 3 h (in vivo) after the start of the cisplatin treatment, which emphasizes the importance of early sampling.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Braakhuis, B. J. M., Ruiz van Haperen, V. W. T., Welters, M. J. P. & Peters, G. J. (1995). Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A: 2335–2340.
Burnouf, D., Daune, M. & Fuchs, R. P. P. (1987). Spectrum of cisplatin-induced mutations in Escherichia coli. Proc Natl Acad Sci USA 84: 3758–3762.
Carey, T. E., Wolf, G. T., Baker, S. R. & Krause, C. J. (1990). Cell surface antigen expression and prognosis. Head and Neck Cancer, 2, Fee WE, Goepfert H, Johns ME, Ward PH (eds). 77–82, BC Decker: Toronto
Eastman, A. (1986). Reevaluation of interaction of cis-dichloro(ethylenediammine)-platinum(II) with DNA. Biochemistry 25: 3912–3915.
Fichtinger-Schepman, A. M. J., Van der veer, J. L., Den Hertog, J. H. J., Lohman, P. H. M. & Reedijk, J. (1985). Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707–713.
Fichtinger-Schepman, A. M. J., Van Oosterom, A. T., Lohman, P. H. M. & Berends, F. (1987). cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cisdiamminodichloroplatinum(II). Cancer Res 47: 3000–3004.
Fichtinger-Schepman, A. M. J., Van der Velde-Visser, S. D., Van Dijk-Knijnenburg, H. C. M., Van Oosterom, A. T., Baan, R. A. & Berends, F. (1990). Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct information. Cancer Res 50: 7887–7894.
Fichtinger-Schepman, A. M. J., Van Dijk-Knijnenburg, H. C. M., Dijt, F. J., Van der Velde-Visser, S. D., Berends, F. & Baan, R. A. (1995a). Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts:consequences for the accurate quantification of the adducts in (cellular) DNA. J Inorg Biochem 58: 177–191.
Fichtinger-Schepman, A. M. J., Van Dijk-Knijnenburg, H. C. M., Van der Velde-Visser, S. D., Berends, F. & Baan, R. A. (1995b). Cisplatin- and carboplatin-DNA adducts: is Pt-AG the cytotoxic lesion?. Carcinogenesis 16: 2447–2453.
Fisch, M. J., Howard, K. L., Einhorn, L. H. & Sledge, G. W. (1996). Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res 2: 1063–1066.
Gupta-Burt, S., Shamkhani, H., Reed, E., Tarone, R. E., Allegra, C. J., Pai, L. H. & Poirier, M. C. (1993). Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiology Biomarkers 2: 229–234.
Hill, B. T., Shellard, S. A., Fichtinger-Schepman, A. M. J., Schmoll, H. J. & Harstrick, A. (1994). Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anti-Cancer Drugs 5: 321–328.
Johnsson, A. & Cavallin-Ståhl, E. (1996). A topographic study on the distribution of cisplatin in xenografted tumors on nude mice. Anti-Cancer Drug 7: 70–77.
Kelland, L. R., Jones, M., Abel, G., Valenti, M., Gwynne, J. & Harrap, K. R. (1992). Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol 30: 43–50.
Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A. & Kerbel, R. S. (1993). Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294–3298.
Korst, A. E. C., Van der Sterre, M. L. T., Eeltink, C. M., Fichtinger-Schepman, A. M. J., Vermorken, J. B. & Van der Vijgh, W. J. F. (1998). Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. Clin Cancer Res (in press)
Kubota, T., Inoue, S., Furukawa, T., Ishibiki, K., Kitajima, M., Kawamura, E. & Hoffman, R. M. (1993). Similarity of serum-tumor pharmacokinetics of antitumor agents in man and mice. Anticancer Res 13: 1481–1484.
Los, G., Blommaert, F. A., Barton, R., Heath, D. D., Den Engelse, L., Hanchett, C., Vicario, D., Weisman, R., Thomas Robbins, K. & Howell, S. B. (1995). Selective intra-artial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol 37: 150–154.
Motzer, R. J., Reed, E., Perera, F., Tang, D., Shamkhani, H., Poirier, M. C., Tsai, W. Y., Parker, R. J. & Bosl, G. J. (1994). Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 73: 2843–2852.
Parker, R. J., Dimery, I. W., Dabholkar, M., Vionnet, J. & Reed, E. (1993). Platinum-DNA adduct in head and neck cancer patients receiving cisplatin and carboplatin chemotherapy. Int J Oncol 3: 331–335.
Pizao, P. E., Lyaruu, D. M., Peters, G. J., Van Arke-Otte, J., Winograd, B., Giaccone, G. & Pinedo, H. M. (1992). Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. Br J Cancer 66: 660–665.
Poirier, M. C., Reed, E., Litterst, C. L., Katz, D. & Gupta-Burt, S. (1992). Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52: 149–153.
Poirier, M. C., Reed, E., Shamkhani, H., Tarone, R. E. & Gupta-Burt, S. (1993). Platinum drug–DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect 99: 149–154.
Reed, E., Ozols, R. F., Tarone, R., Yupsa, S. H. & Poirier, M. C. (1988). The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 9: 1909–1911.
Reed, E., Parker, R. J., Gill, I., Bicher, A., Dabholkar, M., Vionnet, J. A., Bostick-Burton, F., Tarone, R. & Muggia, F. M. (1993). Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 53: 3694–3699.
Schellens, J. H. M., Ma, J., Planting, ASTH, Van der Burg, M. E. L., Van Meerten, E., De Boer-Dennert, M., Schmitz, P. I. M., Stoter, G. & Verweij, J. (1996). Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumour response in patients with solid tumours. Br J Cancer 73: 1569–1575.
Siddik, Z. H., Boxall, F. E. & Harrap, K. R. (1987). Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal chem 163: 21–26.
Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W. & Frei, E. (1990). Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457–1461.
Tomayko, M. & Reynolds, C. P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148–154.
Van Dongen, GAMS, Braakhuis, B. J. M., Leyva, A., Hendriks, H. R., Kipp, B. B. A., Bagnay, M. & Snow, G. B. (1989). Anti-tumor and differentiation-inducting activity of N N-dimethylformamide (DMF) in head and neck cancer xenografs. In J Cancer 43: 285–292.
Welters, M. J. P., Fichtinger-Schepman, A. M. J., Baan, R. A., Hermsen, MAJA, Van der Vijgh, W. J. F., Cloos, J. & Braakhuis, B. J. M. (1997a). Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer 71: 410–415.
Welters, M. J. P., Maliepaard, M., Jacobs-Bergmans, A. J., Baan, R. A., Schellens, J. H. M., Ma, J., Van der Vijgh, W. J. F., Braakhuis, B. J. M. & Fichtinger-Schepman, A. M. J. (1997b). Improved32 P-postlabelling assay for the quantification of the major platinum-DNA adducts. Carcinogenesis 18: 1767–1774.
Yarema, K. J., Lippard, S. J. & Essigmann, J. M. (1995). Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Res 23: 4066–4072.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Welters, M., Fichtinger-Schepman, A., Baan, R. et al. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Br J Cancer 79, 82–88 (1999). https://doi.org/10.1038/sj.bjc.6690015
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690015
Keywords
This article is cited by
-
Insights into the structure–activity relationships of chiral 1,2-diaminophenylalkane platinum(II) anticancer derivatives
JBIC Journal of Biological Inorganic Chemistry (2015)
-
Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay
JBIC Journal of Biological Inorganic Chemistry (2011)
-
In vivo detection of DNA adducts induced by cisplatin using capillary HPLC–ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster
Analytical and Bioanalytical Chemistry (2008)
-
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor
Cancer Chemotherapy and Pharmacology (2008)